The earnings call conveyed a strong positive sentiment driven by the successful initial launch of Sephience and the company's financial position. However, challenges with government payer policy finalizations and the uncertainty around Emflaza's future revenue potential were noted.
Company Guidance
During PTC Therapeutics' Third Quarter 2025 Earnings Conference Call, the company provided guidance by narrowing its 2025 full-year revenue projection to a range of $750 million to $800 million, citing strong performance and the successful launch of Sephience. The quarter's total revenue was reported at $211 million, with Sephience contributing $19.6 million—$14.4 million from the U.S. and $5.2 million from outside the U.S. The company highlighted that 521 patient start forms had been received from U.S. centers as of September 30, indicating strong initial demand across all key patient segments. Additionally, PTC emphasized its strong financial position, ending the third quarter with approximately $1.68 billion in cash, and reaffirmed its goal of reaching cash flow breakeven. The call also mentioned ongoing regulatory and development activities for other programs, including votoplam for Huntington's disease and vatiquinone for Friedreich's ataxia.
Strong Sephience Launch
Sephience generated $19.6 million in revenue within the quarter, with $14.4 million in the U.S. and $5.2 million ex-U.S. The company received 521 patient start forms from U.S. centers as of September 30.
Positive Financial Guidance
PTC Therapeutics narrowed its full-year revenue guidance to $750 million to $800 million, the upper end of the initial range.
Robust Phe Reduction Data
The AMPLIFY study demonstrated Sephience resulted in an average of 70% greater reduction in phenylalanine levels compared to BH4, highlighting its efficacy.
Strong Cash Position
PTC ended the third quarter with approximately $1.68 billion in cash, enabling strategic growth and R&D activities.
PTC Therapeutics (PTCT) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PTCT Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$67.72
$71.77
+5.98%
Aug 07, 2025
$50.36
$45.38
-9.89%
May 06, 2025
$36.19
$40.76
+12.63%
Feb 27, 2025
$50.57
$55.26
+9.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PTC Therapeutics (PTCT) report earnings?
PTC Therapeutics (PTCT) is schdueled to report earning on Feb 24, 2026, After Close (Confirmed).
What is PTC Therapeutics (PTCT) earnings time?
PTC Therapeutics (PTCT) earnings time is at Feb 24, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.